Chemotherapy responsiveness in a patient with multiply relapsed ameloblastic fibro-odontosarcoma of the maxilla
Research output: Contribution to journal › Article
Colleges, School and Institutes
- Paediatric Drug Development, Children and Young People's Unit, The Royal Marsden NHS Foundation Trust, Sutton, UK; and at the Division of Clinical Studies and Cancer Therapeutics, The Institute of Cancer Research, Sutton, UK.
- Department of Pathology, The Royal Marsden NHS Foundation Trust, Sutton, UK.
- Department of Radiotherapy, The Royal Marsden NHS Foundation Trust, Sutton, UK.
- Head and Neck Unit, The Royal Marsden NHS Foundation Trust, Sutton, UK.
- Department of Radiology, The Royal Marsden NHS Foundation Trust, Sutton, UK.
Ameloblastic fibro-odontosarcoma (AFOS) is an extremely rare malignant odontogenic tumor. Complete surgical excision is the treatment of choice. Deaths due to disease recurrence and/or progression are documented. Here, we report the case of a 15-year-old female with multiple recurrent AFOS. She responded to chemotherapy with ifosfamide and doxorubicin consolidated by stereotactic reirradiation using cyberknife and remained in complete remission 14 months from the end of reirradiation therapy. Chemotherapy with ifosfamide and doxorubicin should be considered in advanced cases of AFOS.
|Number of pages||4|
|Journal||Pediatric Blood & Cancer|
|Early online date||15 Jul 2015|
|Publication status||Published - Nov 2015|
- Ameloblastoma/surgery, Child, Female, Fibrosarcoma/surgery, Humans, Maxillary Neoplasms/surgery, Neoplasm Recurrence, Local/surgery, Radiosurgery, Remission Induction